Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2
Dept of Defense · DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
This notice is not accepting responses (deadline was Jun 23, 2026, 8:00 PM EDT).
Page kept for research and related open opportunities below. For current work in this category, use the related notices or browse hubs.
- Response deadline
- Jun 23, 2026, 8:00 PM EDT
- Posted
- May 26, 2026
- Solicitation
- DARPA-PS-26-124
- Set-aside
- None listed
- Place of performance
- —
- Contracting office
- DEF ADVANCED RESEARCH PROJECTS AGCY · ARLINGTON · VA
- Source
- SAM.gov · updated Jun 1, 2026
Description
The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.
What similar awards have paid
Real federal awards already on the books in a similar lane — so you can size the opportunity, not guess. This is public history, not a bid price, cost estimate, or prediction that you will win.
Typical award size
$517,831
Middle of the pack for similar past awards
Most similar awards fall between $50,502 and $3.57M
Who has won work like this
Public awardees in this lane — useful for competitor scan or teaming ideas, not a ranked list of “best” firms.
- 1AMGEN USA INC1 award$713.89M
- 2ADVANCED TECHNOLOGY INTERNATIONAL3 awards$531.67M
- 3MAPP BIOPHARMACEUTICAL, INC.2 awards$295.66M
- 4EMERGENT BIODEFENSE OPERATIONS LANSING LLC1 award$211.41M
- 5ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)1 award$158.81M
- 6PPD DEVELOPMENT LP2 awards$152.02M
- 7START2 GROUP, INC.1 award$138.08M
- 8BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL2 awards$118.95M
Recent examples
A few of the newest similar awards in our index.
- AURO VACCINES LLCSep 30, 2025Department of Health and Human Services$10.73MSource
- START2 GROUP, INC.Sep 30, 2025Department of Health and Human Services$138.08MSource
- UNIVERSITY LAB PARTNERSSep 30, 2025Department of Health and Human Services$21.12MSource
- CIDARA THERAPEUTICS INCSep 30, 2025Department of Health and Human Services$58.05MSource
- CRYPTOBIOTIXSep 30, 2025Department of Agriculture$47,000Source
- THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTERSep 30, 2025Department of Health and Human Services$1.18MSource
Drawn from official USAspending contract records in our index. Always confirm requirements on the SAM.gov notice before you bid.
Intelligence only — not legal advice or a guarantee of award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Notice ID 0cc7aef506074243baab86c4f451dfe2.